SCHEMBL10043835

SCHEMBL10043835

Cc1cc2c(cn1)cc(-c1cc(NC(=O)Nc3ccc(C(C)C)cc3)ccc1C)c(=O)n2C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 2/20 0.43
HTR2C P28335 2/20 0.43
RAB9A P51151 5/20 0.41
MAPT P10636 5/20 0.41
NPC1 O15118 4/20 0.41
LMNA P02545 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
IDH1 O75874 1/20 0.40
SYK P43405 1/20 0.40
FPR2 P25090 1/20 0.40
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
KDM4E B2RXH2 1/20 0.39
NPSR1 Q6W5P4 1/20 0.37
MYOC Q99972 1/20 0.37
FGFR1 P11362 2/20 0.37
SRC P12931 2/20 0.37
EGFR P00533 1/20 0.37
TP53 P04637 1/20 0.36
KRAS P01116 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10043828 0.91 RAB9A (0.48) RAB9AMAPTNPC1SMN1; SMN2SYK
SCHEMBL10043821 0.89 SYK (0.49) RAB9AMAPTNPC1LMNASMN1; SMN2
SCHEMBL10043829 0.88 SYK (0.41) RAB9AMAPTNPC1SYKFGFR1
SCHEMBL10043825 0.86 FGFR1 (0.48) HTR2AHTR2CRAB9AMAPTNPC1
SCHEMBL10043858 0.86 SYK (0.40) RAB9AMAPTNPC1SYKKDM4E
SCHEMBL12400251 0.85 SYK (0.39) RAB9AMAPTNPC1SYKFGFR1
SCHEMBL10043824 0.85 MAPT (0.42) RAB9AMAPTNPC1SYKKDM4E
SCHEMBL10043823 0.85 HTR2C (0.52) HTR2CRAB9AMAPTNPC1SMN1; SMN2
SCHEMBL10043839 0.84 SYK (0.47) RAB9AMAPTNPC1SYKKRAS
SCHEMBL10043830 0.84 SMARCA2 (0.48) RAB9AMAPTNPC1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC HTR2A 2717/4885HTR2C 2796/4885RAB9A 1818/4885
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC HTR2A 2717/4885HTR2C 2796/4885RAB9A 1818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.